PHVS
PHVS clinical trials: Pharvaris N.V.
Every trial on ClinicalTrials.gov where Pharvaris N.V. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PHVS on the catalyst calendar · PHVS registry changes
- Primary completion Aug 19, 2031Sponsor estimatePhase 3NCT06679881Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and...Pharvaris Netherlands B.V. · Hereditary Angioedema (HAE)Enrolling by invitationPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2026ActualPhase 3NCT06669754Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPharvaris Netherlands B.V. · Hereditary Angioedema (HAE)CompletedPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT07266805Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in...Pharvaris Netherlands B.V. · Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)RecruitingPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2025ActualPhase 2NCT05047185Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIPharvaris Netherlands B.V. · Hereditary AngioedemaTerminatedPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07759141EAP for Deucrictibant Immediate-releasePharvaris Netherlands B.V. · Hereditary AngioedemaAvailablePHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2/Phase 3NCT05396105Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPharvaris Netherlands B.V. · Hereditary AngioedemaEnrolling by invitationPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2022ActualPhase 2NCT04618211Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPharvaris Netherlands B.V. · Hereditary AngioedemaCompletedPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2025ActualPhase 3NCT06343779Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaPharvaris Netherlands B.V. · Hereditary AngioedemaCompletedPHVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2026Sponsor estimatePhase 3NCT05834777Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 ReceptorVanderbilt University Medical Center · Intradialytic HypotensionActive, not recruitingPHVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner